Sub-threshold Photocoagulation of Diabetic Macular Oedema
NCT02309476 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2020-03-17
Summary
Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to decrease the intensity of the burns (invisible burns) showing some landmarks with normal intensity so the investigators can see the area which has been treated. The Pascal® system with EM utilizes 577nm laser wavelength compared to the 532nm laser wavelength which was utilized in previous Pascal® laser studies.
This study aims to demonstrate that 577nm Pascal® with EM has the same efficacy and effectiveness as 532nm Pascal® in the treatment of diabetic macular oedema.
Conditions
- Diabetic Macular Oedema
Interventions
- DEVICE
-
PASCAL Laser, Green Laser 0.75
Barely Visible Pascal laser grid using 532nm "green" wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
- DEVICE
-
PASCAL Laser, Green Laser 1
Barely Visible Pascal laser grid using 532nm "green" wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
- DEVICE
-
PASCAL Laser, 70% Yellow Laser 0.75
Pascal EM at 70% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
- DEVICE
-
PASCAL Laser, 70% Yellow Laser 1
Pascal EM at 70% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid
- DEVICE
-
PASCAL Laser, 40% Yellow Laser 0.75
Pascal EM at 40% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
- DEVICE
-
PASCAL Laser, 40% Yellow Laser 1
Pascal EM at 40% 577nm "yellow" laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the "Landmark" burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
Sponsors & Collaborators
-
Topcon Corporation
collaborator INDUSTRY -
Optos, PLC
collaborator INDUSTRY -
Manchester University NHS Foundation Trust
lead OTHER_GOV
Principal Investigators
-
Paulo Stanga · Manchester Royal Eye Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2014-12-31
- Completion
- 2015-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema
NCT01928654 ·Status: UNKNOWN ·Phase: NA
-
Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies
NCT05976139 ·Status: RECRUITING ·Phase: NA
-
Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.
NCT01766362 ·Status: COMPLETED ·Phase: PHASE3
-
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
NCT07295704 ·Status: RECRUITING
-
Micropulse 810 Nanomolar (nm), Diode Laser for Diffuse Diabetic Macular Edema
NCT00552435 ·Status: UNKNOWN ·Phase: PHASE2
-
Photobiomodulation for the Treatment of Diabetic Macular Edema
NCT02457975 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Changes in Macular Thickness After Patterns Scan Laser
NCT00563628 ·Status: TERMINATED ·Phase: PHASE4
-
Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema
NCT00701181 ·Status: TERMINATED ·Phase: PHASE2
-
Micropulsed Laser in Association With Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED).
NCT02650050 ·Status: TERMINATED ·Phase: NA
-
Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema
NCT01045239 ·Status: UNKNOWN ·Phase: PHASE2
-
Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser
NCT01304225 ·Status: UNKNOWN ·Phase: PHASE3
-
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
NCT00682240 ·Status: COMPLETED ·Phase: PHASE4
-
Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
NCT04847635 ·Status: RECRUITING ·Phase: NA
-
To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema
NCT02462304 ·Status: UNKNOWN ·Phase: PHASE4
-
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
NCT06985706 ·Status: RECRUITING ·Phase: PHASE3
-
Micropulse for Suppression of Diabetic Macular Edema
NCT03519581 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Effects of Selective Photocoagulation for the Treatment of Diabetic Macular Edema
NCT01355692 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
NCT02554747 ·Status: COMPLETED ·Phase: NA
-
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
NCT00563043 ·Status: TERMINATED ·Phase: PHASE4
-
Comparing Conventional Grid Laser Photocoagulation and Subthreshold Micropulse Laser in Diabetic Macular Edema Using OCT Angiography
NCT05416099 ·Status: UNKNOWN
-
A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema
NCT02121262 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema
NCT05759884 ·Status: UNKNOWN ·Phase: NA
-
"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study
NCT02960828 ·Status: UNKNOWN ·Phase: NA
-
OCT-angiography in Diabetic Patients
NCT02870803 ·Status: UNKNOWN
-
Comparison of Treatments in Diabetic Macular Edema
NCT05715385 ·Status: COMPLETED ·Phase: PHASE4